For example, ligand-based IL-13Rα2-targeting CAR T cells whose binding domain utilizes a modified IL-13 ligand have shown promise for the treatment of childhood glioblastoma multiforme (GBM), resulting in tumor regression with enhanced IFN-γ signaling to activate the host immune system (63, 64). This evidence concerns the gene IL13RA2 and glioblastoma.